Median Technologies SA
PAR:ALMDT
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
2.035
7.4
|
Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one ALMDT stock under the Base Case scenario is 7.708 EUR. Compared to the current market price of 4.035 EUR, Median Technologies SA is Undervalued by 48%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Median Technologies SA
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for ALMDT cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Median Technologies SA
Balance Sheet Decomposition
Median Technologies SA
Current Assets | 31.9m |
Cash & Short-Term Investments | 19.6m |
Receivables | 11m |
Other Current Assets | 1.3m |
Non-Current Assets | 4m |
Long-Term Investments | 355k |
PP&E | 1.9m |
Intangibles | 1.7m |
Other Non-Current Assets | -1k |
Current Liabilities | 22.7m |
Accrued Liabilities | 5.9m |
Short-Term Debt | 11k |
Other Current Liabilities | 16.8m |
Non-Current Liabilities | 23.5m |
Long-Term Debt | 18.1m |
Other Non-Current Liabilities | 5.4m |
Earnings Waterfall
Median Technologies SA
Revenue
|
22.2m
EUR
|
Cost of Revenue
|
1m
EUR
|
Gross Profit
|
23.2m
EUR
|
Operating Expenses
|
-46.3m
EUR
|
Operating Income
|
-23.1m
EUR
|
Other Expenses
|
134k
EUR
|
Net Income
|
-23m
EUR
|
Free Cash Flow Analysis
Median Technologies SA
EUR | |
Free Cash Flow | EUR |
ALMDT Profitability Score
Profitability Due Diligence
Median Technologies SA's profitability score is 46/100. The higher the profitability score, the more profitable the company is.
Score
Median Technologies SA's profitability score is 46/100. The higher the profitability score, the more profitable the company is.
ALMDT Solvency Score
Solvency Due Diligence
Median Technologies SA's solvency score is 48/100. The higher the solvency score, the more solvent the company is.
Score
Median Technologies SA's solvency score is 48/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ALMDT Price Targets Summary
Median Technologies SA
According to Wall Street analysts, the average 1-year price target for ALMDT is 16.966 EUR with a low forecast of 11.11 EUR and a high forecast of 22.26 EUR.
Dividends
Current shareholder yield for ALMDT is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
ALMDT Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
MEDIAN Technologies SA engages in the development and market of software publishing solutions and provision of services in the field of medical imaging in oncology. The company is headquartered in Valbonne, Paca. The company went IPO on 2011-05-20. The firm develops lesion management solutions (LMS) to objectively measure and track cancerous or suspicious lesions, distribute a standardized oncologic report and centralize the lesion information for multidisciplinary review. The LMS line includes such products as LMS-Lung, a clinical application for the detection, evaluation and follow-up of lesions identified in CT images covering the chest; LMS-Track, a clinical application for the follow-up of oncology patients; and LMS-Liver, a clinical application for the initial evaluation and the follow-up of liver metastases and any other lesions identified in CT images covering the liver. The firm operates one subsidiary, Median Technologies Inc, based in the United States.
Contact
IPO
Employees
Officers
The intrinsic value of one ALMDT stock under the Base Case scenario is 7.708 EUR.
Compared to the current market price of 4.035 EUR, Median Technologies SA is Undervalued by 48%.